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Abstract
Background: Liver transplantation is the most effective therapy for cirrhosis-associated hepatocellular carcinoma
(HCC) but its utility is limited by post-transplant tumor recurrence. Use of the Milan, size-based criteria, has reduced
recurrence rate to less than 10% but many patients remain ineligible. Reduction of tumor size with local therapies
has been used to “downstage” patients to allow them to qualify for transplantation, but the optimal criteria to
predict tumor recurrence in these latter patients has not been established. The existence of a progenitor cell
population, sometimes called cancer stem cells (CSCs), has been proposed to be one mechanism accounting for
the chemotherapy resistance and recurrence of hepatocellular carcinoma. The aim of this study was to determine if
transcatheter arterial chemoemolization (TACE) treated tumors have increased CSC marker expression and whether
these markers could be used to predict tumor recurrence.
Methods: Formalin fixed specimens were obtained from 39 HCC liver explants (23 with no treatment and 16 after
TACE). Immunohistochemical staining was performed for EpCAM, CD44, CD90, and CD133. Staining for each marker
was scored 0–3 by evaluating the number and intensity of positive tumor cells in 5 hpf of tumor in each specimen.
Results: TACE treated tumors displayed greater necrosis and fibrosis than non-TACE treated samples but there
were no differences in morphology between the viable tumor cells of both groups. In TACE treated specimens, the
staining of both EpCAM and CD133 was greater than in non-TACE specimens but CD44 and CD90 were the same.
In the TACE group, the presence of high EpCAM staining was associated with tumor recurrence. Four of ten EpCAM
high patients recurred while 0 of 6 EpCAM low patients recurred (P = 0.040). None of the other markers predicted
recurrence.
Conclusion: High pre-transplant EpCAM staining predicted HCC recurrence. This suggests that the abundance of
tumor cells with a CSC phenotype may be a critical factor in the likelihood of tumor recurrence in patients
receiving liver transplantation after TACE.
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Background
Hepatocellular carcinoma (HCC) is one of the most
prevalent cancers in Asia and Africa, and ranks as the
third most frequent cause of cancer-related death [1,2].
Its incidence is increasing in the western world due to
increased prevalence of hepatitis virus C infection [3,4].
Although considerable advances have been made in the
treatment of HCC, particularly through surgical resec-
tion, liver transplantation, tumor ablation and chemo-
therapy, the mortality rate remains high, and tumor
recurrence after surgery or transplantation remains a
frequent problem. A better understanding of the biology
of the tumors and the factors that predict recurrence
post surgery would have a major impact on the manage-
ment of the disease.
For the majority of patients who develop HCC in the
setting of cirrhosis, liver transplantation remains the pri-
mary surgical approach. While early experience showed
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a high proportion of patients recurring, current practice
of limiting transplantation eligibility to patients with
lower tumor volume and absence of vascular invasion,
the Milan criteria [5], has decreased recurrence rate to
less than 10% at most centers [6]. Unfortunately, there is
broad recognition that criteria based solely on tumor
size, while helpful, include some patients who will recur
and likely exclude some patients from transplantation
who would not have recurred. In addition patients fre-
quently receive local therapy to the tumor prior to trans-
plant, and in many cases, tumor shrinkage via
therapeutic “downstaging” is required for patients to
meet transplant eligibility requirements [7,8].
Successful downstaging has been shown to result in
overall transplant outcomes similar to those achieved for
patients who start out within Milan criteria [9], however,
approximately 15-30% of patients for whom downstaging
is attempted progress in spite of treatment and thus are
excluded from transplantation [9,10]. The success of
downstaging, therefore, is partly a result of the ability of
the followup period to exclude patients with aggressive
and poorly responsive tumors. The biological behavior
of the tumors post-treatment is variable and the concern
has been raised that in some cases, TACE itself might
select for or induce more aggressive tumors [11].
Whether or not this is relevant to subgroups of patients
and whether a better understanding of tumor biology
might lead to improved ability to predict post-transplant
tumor behavior remains uncertain.
Hepatocellular carcinomas consist of a heterogeneous
group of cells that have varying ability to proliferate and
seed new tumors [12]. It has been proposed that a sub
population of cells variously called tumor initiating cells,
cancer progenitor cells, or cancer stem cells (CSCs) serves
as a proliferation reservoir, is able to seed new tumors
with very low inoculum levels and is responsible for re-
currence and metastases. While these cells are not true
pluripotent stem cells, they possess characteristics of stem
cells in that they can give rise to all the cell types in the
tumor. They are relatively chemotherapy resistant and are
a strong candidate for the source of intrahepatic HCC
recurrence post liver transplantation [13]. There is no gen-
eral consensus on the best markers to identify these cells
and as a result there is no clear consensus of whether they
play a major role in HCC. Several prior studies have exam-
ined CD133, CD44, CD90, CD13 and EpCAM as possible
candidate CSC markers in HCC [14-19].
Several makers, particularly EpCAM and CK19 have
been shown to correlate with more aggressive tumor be-
havior [20,21]. We therefore sought to determine if stem
cell marker expression predicted tumor recurrence after
transplantation, particularly in patients who had under-
gone transcatheter arterial chemoembolization (TACE).
In the present study, we compared the phenotypic
expression of four markers in HCCs resected from
patients undergoing liver transplantation either with or
without prior TACE treatment of the tumor, and deter-
mined whether any of these correlated with the likeli-
hood of tumor recurrence. The results demonstrate that
EpCAM and CD133 positive cells were higher in the
post-TACE tumors and higher pretransplant EpCAM




The research involving human subjects reported in this
study involved retrospective analysis of tissue samples
and de-identified clinical data from patients who had
agreed to allow their explanted tissue samples to be
included in a tissue Biorepository. The research was
approved by the University of Kansas Medical Center
Human Subjects Committee, under approval numbers
HSC# 11378 and HSC#12800. All participating subjects
gave written informed consent. All clinical investigations
were conducted according to the principles expressed in
the Declaration of Helsinki.
Tissue collection
Samples of paraffin-embedded sections of explanted
HCC and adjacent liver specimens were obtained from
the University of Kansas Cancer Center's (KUCC) Bios-
pecimen Shared Resource or the University of Kansas
Liver Center Tissue Bank. These were obtained from 39
patients who underwent liver transplantation at the Uni-
versity of Kansas Medical Center (KUMC) from January,
2004 to July ,2010. Clinical data associated with the spe-
cimens was recorded without patient identification and
all procedures were approved by the Human Studies
Committee at KUMC. Sixteen cases were from patients
whose tumor had been previously treated by transcath-
eter arterial chemoembolization (TACE) using doxorubi-
cin and lipiodol and 23 cases were from patients who
did not receive any specific tumor treatment prior to
liver transplantation. All post-TACE HCCs examined in
this study had microscopic foci of viable carcinoma as
well as coagulative necrosis consistent with the effect of
therapy. Survival data were determined at the last
follow-up period for living patients. For those patients in
whom tumor relapse occurred, relapse time was taken to
be the interval between the date of liver transplantation
and the date of diagnosis of any type of relapse with ei-
ther intrahepatic recurrence or extrahepatic metastasis
defined as the end points.
Immunohistochemical staining
Paraffin-embedded, formalin-fixed liver tissues were cut
into 5-μm sections and placed on polylysine-coated
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slides. Antigen retrieval was achieved with a steam pres-
sure cooker for 10 min in sodium citrate buffer (10 mM
sodium citrate 0.05% Tween 20, pH 6.0). The sections
were incubated with 3% hydrogen peroxide/PBS for
20 min and then rinsed twice in washing buffer TBS-T
for 5 min each. Slides were then blocked by incubation
for 1 h at room temperature with 5% goat serum in
TBS-T. After blocking, samples were incubated with
primary antibodies (rabbit anti-CD133, cat# ab19898,
Abcam, 1:250; anti-EpCAM cat# ab68892, Abcam, 1:1000;
anti-CD44, cat# ab65829, Abcam 1:250, anti-CD90, cat#
ab92574, Abcam,1:100) in 1% goat serum in TBS-T) and
incubated overnight at 4°C. After washing, slides were
then incubated with HRP-labeled Polymer (EnVision +
System, Dako, Carpinteria, CA) and either anti-rabbit
(K4002) or anti-mouse (K4000) secondary antibody, for 1
h at room temperature, and then developed with AEC
substrate Chromogen (Dako, K3464) and counterstained
by Mayer’s hematoxylin.
For the evaluation of CD133, CD90, CD44 and
EpCAM staining, three independent investigators exam-
ined the slides without related clinical information. The
intensity of CD133, CD90, CD44 and EpCAM staining
was scored on a four point scale. For CD90 and CD44,
staining varied little in intensity and was primarily differ-
entiated by the number of positive cells. Score 0 was less
than 25% positive; score 1 was 25%-50% positive; score 2
was 50%-75% positive; and score 3 was higher than 75%
of cells positive. For EpCAM and CD133, there was var-
iablity in staining intensity as well as in number of posi-
tive cells. For these markers, a composite scale taking
into account both number and intensity was used. When
high intensity staining was present, the scale was the
same as for CD90 and CD44, but when staining of
varying intensity was present in most cells, the score was
based on overall intensity with score 1 being no staining,
score 2 faint staining, score 3 moderate staining and
score 4 representing strong staining. The final score was
the mean value of scores from three observers. Examples
of these are shown in Figure 1. Scores 0 and 1 were con-
sidered as low expression, whereas scores 2 and 3 were
considered as high expression.
Statistical analysis
Statistical analysis and graphical presentation were per-
formed using SPSS (v17.0) software for Windows (SPSS
Inc., Chicago, IL). The clinicopathological parameters
were compared with the Mann–Whitney U-test and
Wilcoxon test .CD44, CD90, CD133 and EpCAM ex-
pression were compared with the χ2 test according to
the immunoreactive score of each tissue section. The
Cox regression model was used to perform univariate
and multivariate analyses. The recurrence rate was
calculated using the Kaplan–Meier method, and the
resulting curves were compared by the log-rank test. P <
0.05 was considered significant.
Results
Clinico-pathological features
Clinico-pathological characteristics of the post-TACE
and non-TACE HCCs are shown in Table 1 and the
details of individual patients, including the reasons for
the decision whether or not to perform TACE are listed
in Tables 2 and 3. In the post-TACE group, the under-
lying disease etiology was HCV in 13 cases, HBV in 2
cases and cryptogenic cirrhosis in 1 case. In the non-
TACE group, 21 cases were due to HCV, 1 case to HBV
and one to primary sclerosing cholangitis. These patients
reflect a period when transplant wait times were rela-
tively short at the University of Kansas and patients with
similar tumor sizes sometimes underwent TACE and
other times did not. For the TACE group, 8/16 (50%)
patients were outside of Milan and the TACE was per-
formed for downstaging, but the other half of the
patients were within Milan criteria and the TACE was
performed in an attempt to prevent progression. For the
non-TACE group 21/23 (91%) were within Milan criteria
and only 2/23 (9%) were outside of Milan criteria but
received transplants based on their MELD scores alone.
Mean largest tumor size was greater in the TACE group
(3.8 vs 2.9 cm) as was AFP, but these differences were
not statistically significant (Table 1) Other features such
as tumor number, tumor differentiation, gender , age, or
TNM stage did not differ between the groups. We
attempted to determine pre-transplant tumor growth
rate to assess whether the TACE patients had more rap-
idly growing tumors than non-TACE patients, but this
did not appear to be the case. Multiple pre-TACE im-
aging studies were available in 9/16 TACE patients and
demonstrated a mean tumor diameter increase rate of
0.08 ± 0.12 cm/month. Multiple imaging studies were
only available in 5/23 non-TACE patients but in those
patients growth rates were somewhat greater at 0.16 ±
0.15 cm/month. Due to the limited numbers of patients
with multiple scans it is not possible to determine the
biological significance of this finding.
Confluent coagulative necrosis was present in all post-
TACE HCC samples but not in any of the non-TACE
HCCs. TACE treated tumors displayed greater necrosis,
more fibrosis and less viable cells than non TACE treated
samples. There were no differences in cell morphology,
state of differentiation or nuclear/cytoplasmic ratio
between the viable treated and nontreated tumor cells.
Immunohistochemical characteristics of HCC tumors
All the presumptive CSC biomarkers were detected in
either membranes or cytoplasm of some tumor cells.
They showed a variety of staining patterns, including
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differences in staining intensity and percentage of posi-
tive cells. Duplicate sections or different areas for each
tumor showed a good level of homogeneity for both stained
cell percentages and intensities. Figure 1 demonstrates
examples of the immunostaining patterns observed as an
example for each expression intensity category.
The expression score of each of the markers was
significantly higher in tumor cells than in adjacent liver
tissue (Table 4, Figure 2). The expression of CD133 and
EpCAM was significantly higher in the post-TACE group
than in the non-TACE group (Table 4). There was no
significant difference in CD44 and CD90 staining inten-
sity in the TACE and non-TACE groups.
As CD133 and EpCAM were the markers that asso-
ciated with post-TACE status, we wanted to determine if
variable expression of these markers predicted tumor
characteristics. Post-TACE tumors were categorized into
subgroups with either low (scores 0 and 1) or high
(scores 2 and 3) expression of either CD133 or EpCAM.
Clinical-pathological characteristics of patients with
tumors in these categories are summarized in Table 5.
There were no differences in gender, time interval
between TACE and transplantation, number of TACE
procedures performed, age, serum AFP, tumor size, or
TNM stage in any of the groups. Tumor differentiation,
however, was different between the EpCAM high and
EpCAM low groups (p = 0.024). Univariate analysis
showed that high EpCAM status was significantly
associated with more undifferentiated tumor histology
and having undergone TACE (Table 6). Multivariate
analysis showed that the relative risk of having high
Table 1 Clinical and pathological features of samples






Age (years) 56(48–68) 55(45–68) 0.363
Gender (F/M) 2/14 5/18 0.460
AFP (ng/ml) 660(3–7245) 382(3–2809) 0.114
Tumor Num. (Single/Multiple) 8/8 14/9 .0.365
Largest Tumor size
Mean (range) (mm)








Figure 1 Pattern and intensity of staining for potential cancer stem cell markers in hepatocellular carcinoma specimens. Formalin-fixed
paraffin-embedded human HCC samples were immunostained for CD90, CD44, CD133, and EpCAM and intensity of staining was assessed as
described in methods. For each marker, example images are shown demonstrating the staining pattern for each of the intensity grades.
Zeng et al. BMC Cancer 2012, 12:584 Page 4 of 11
http://www.biomedcentral.com/1471-2407/12/584



















Reasons not to TACE
A B C D E
N1 62 F HCV 20 2 1.9, 1.6 Y N/A 1.6 49 N N/A X
N2 48 M HCV 13 1 1.9 Y N/A 2 340 N N/A X
N3 49 F HCV 1207 3 1.3, 2.0, 2.5 Y N/A 3.4 188 N N/A X
N4 52 F HCV 107 2 1.0, 2.1 Y N/A 2.3 160 N N/A X
N5 65 M HCV 5.3 2 N/A N/A N/A 1.1 12 N N/A X
N6 56 M HBV 4 1 4.8 Y N/A 3.5 59 N N/A X
N7 68 M HCV 1327 2 1.4, 2.6 Y 0.12 2.8 205 N N/A X
N8 46 F HCV 2809 1 3.8 Y 0.2 6 115 N N/A X X
N9 48 M HCV 686 1 3 Y 0.4 3.6 116 N N/A X
N10 53 M HCV 3 1 1.5 Y 0.1 2.5 190 N N/A X
N11 45 M HCV 4 1 5.4 N N/A 5.1 45 N N/A X
N12 57 M HCV 6 1 2.8 Y N/A 4 41 Y 24mo. X
N13 55 M HCV 11 2 0.9, 1.6 Y N/A 2.3 38 N N/A X
N14 49 M HCV 7 1 5.3 N N/A 5.5 87 N N/A X
N15 53 M HCV 2461 1 2.8 Y N/A 5 95 N N/A X
N16 55 M HCV 7 2 1.0, 0.8 Y N/A 1 0 N N/A X
N17 52 M HCV 18 1 2.5 Y N/A 3.1 128 N N/A X X
N18 56 F HCV 19 1 3.3 Y N/A 3.5 117 N N/A X X
N19 68 M HCV 9 2 2.2, 1.6 Y 0 2 377 N N/A X X
N20 56 M HCV 7 1 N/A N/A N/A 1 0 N N/A X
N21 53 M PSC 40 2 N/A N/A N/A 0.3 0 N N/A X
N22 64 M HCV 20 1 2.1 Y N/A 3.5 179 N N/A X
N23 49 M HCV 3.6 1 N/A N/A N/A 1.5 0 N N/A X
A = Patient was within Milan.
B = Outside Milan but eligible for transplant by MELD with a short waiting time expected.
C = Patient could not tolerate procedure.
D = Tumor not appreciated pre-op.
E = Procedure planned, not able to perform prior to transplant.







































T1 61 M Cryptogenic 7254 1 6.3 N N/A 5 241 N X
T2 50 M HCV 27.9 1 3.5 Y 0.02 3.7 327 Y 14.5mo. X
T3 53 M HCV 27.6 1 3.5 Y N/A 5 263 N X
T4 54 M HCV 67 3 2.9, 1.6, 1 Y N/A 3 153 N X
T5 58 M HCV 4 1 7.6 N 0 7.6 82 N X
T6 59 M HCV 4 2 3.1, 3.5 N 0.03 3.5 127 N X
T7 65 F HBV 667 1 2.5 Y 0.33 2.5 167 N X
T8 68 F HCV 18 1 6 N N/A 4.7 174 N X
T9 57 M HCV 43 2 3.2, 1.8 N N/A 3.2 141 N X
T10 48 M HCV 40 4 3.5, 2.8, 2.5, 1.0 N 0.23 3.5 190 Y 6mo. X
T11 49 M HCV 2000 1 3.5 Y 0.003 3.5 73 N X
T12 53 M HCV 189 3 2.4, 0.6, 0.3 Y N/A 2.4 377 N X
T13 54 M HCV 8 5 2.1, 1.5, 1.4, 1, .7 N 0 4 241 N X
T14 58 M HCV 188 1 6.3 N 0.12 5.5 345 Y 13mo. X
T15 57 M HCV 3 3 2.8, 1.9, 1.3 Y N/A 2 263 Y 18.5mo. X
T16 62 M HBV 20 2 1.7, 1.6 Y 0 2 153 N X
A = Downstage to achieve eligibility.
B = Bridge to transplant.

















EpCAM staining was independently influenced only
by TACE status (relative risk 5.88 for TACE vs. no
TACE, Table 7).
Impact of CSC markers on tumor recurrence
We next examined whether EpCAM or CD133 staining
intensity correlated with tumor recurrence. All patients
included in this study were followed for at least two
years post transplant. Four of the sixteen post-TACE
patients had tumor recurrences. There was no effect of
CD133 staining on recurrence. Two of the recurrences
were in the 12 patients with CD133 high tumors and 2
were in the 4 patients with CD133 low tumors. In con-
trast, all 4 recurrences were in the 10 patients with
EpCAM high tumors. None occurred in the 6 patients
with EpCAM low tumors (median follow-up period,
33 months). Probability of recurrence in these groups
is presented in Figure 3. Tumor recurrence rates at
Figure 2 Marker immunostaining in tumor and uninvolved liver. Sections were immunostained as described and comparison samples are
shown of HCC and surrounding non-tumor liver from the same specimens for CD133, EpCAM, CD90 and CD44.
Table 4 Comparison of immunhistochemical staining score between HCC and adjacent liver tissues in TACE-treated
and untreated tumors
HCC tissues (n-39) Adjacent tissues (n = 39) P TACE (n = 16) No-TACE (n = 23) P
CD90 1.3 ± 0.9 0.6 ± 0.7 0.002 1.69 ± 0.87 1.17 ±0.83 0.856
CD44 2.0 ± 1.0 1.5 ± 0.8 0.013 2.06 ± 0.85 1.95 ± 165 0.743
CD133 1.6 ± 1.2 1.2 ± 0.9 0.042 2.25 ± 1.00 1.17 ± 1.07 0.003
EpCAM 1.5 ± 1.1 0.6 ± 0.6 <0.001 2.00 ± 1.03 1.17 ± 0.89 0.016
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post-transplantation were 40 % (4/10) in EpCAM high
and 0% in EpCAM low post-TACE patients (Figure 3,
p = 0.040). In the 23 non-TACE treated patients, there
was only one recurrence so the impact of marker stain-
ing could not be assessed.
Discussion
The recognition that adherence to size and invasion
based criteria such as the Milan criteria greatly reduces
post-transplant tumor recurrence [5] has made it is pos-
sible to improve survival outcomes for large numbers of
cirrhotic patients with relatively small HCCs. The devel-
opment of effective therapies, such as TACE, that shrink
tumor size has allowed a larger number of patients to
undergo transplantation [9]. However, with increasing
understanding that factors other than tumor size may
predict tumor phenotype, there is a need to revisit the
optimal criteria for predicting post-transplant recurrence.
The recent findings that certain progenitor cell markers
portend poor prognosis of HCC [20] promoted us to in-
vestigate the role of these in post-transplant tumor
recurrence.
Hepatocellular carcinoma has a number of characteris-
tics that are compatible with the existence of a circulat-
ing cancer stem cell (CSC) population [22,23]. The
tumors are heterogeneous, frequently demonstrate intra-
hepatic recurrence after liver transplantation in spite of
the absence of known metastatic disease, and different
subpopulations of cells derived from HCCs have dramat-
ically different abilities to form tumors in immuno-
deficient mice [15,16]. While phenotypic identification
of these cells within tumors has been controversial, evi-
dence exists supporting the importance of CD133,
CD90, CD13, EpCAM and CD44 as potential markers
to identify this cell population [14-19,24]. These obser-
vations have led to the widespread belief that CSCs
are an important part of HCC biology. In spite of this
Table 5 Impact of marker status on clinical and pathological tumor features in TACE treated HCC
EpCAM CD133
Low (n = 6) High (n = 10) P Low (n = 4) High (n = 12) P
Age (year) 58(53–65) 56(48–68) 0.236 52(48–57) 58(49–68) 0.070
Gender (F/M) 1/5 1/9 0.696 0/4 2/12 0.383
AFP (ng/ml) 1333(4–7254) 256(3–2000) 0.289 297(8–43) 870(3–7254) 0.177
Interval between 189(82–345) 224(73–337) 0.479 260(188–327) 194(73–377) 0.217
TACE and Tx (days)
More than one TACE 1/6 3/10 0.639 2/4 2/12 0.329
Tumor Size (mm) 45(25–76) 34(20–55) 0.181 36(32–40) 39(20–76) 0.744
Tumor differentiation 0.024 0.834
Well 0 1 0 1
Moderately 6 3 3 8
Poor 0 6 1 3
TNM Stages 0.302 0.248
I 4 4 1 7
II 2 6 3 5
Table 6 Univariate analyses of clinical and tumor factors associated with EpCAM/CD133 in 39 HCC patients
Variables Epcam CD133
P value OR 95% CI P value OR 95% CI
Age (≥55/<55) 0.719 1.27 0.34-4.73 0.726 1.25 0.39-4.36
Gender (Female/male) 0.656 1.50 0.25-9.00 0.101 4.17 0.76-23.07
AFP (ng/ml) (≥20/<20) 0.066 3.75 0.92-15.34 1.000 1.00 0.29-3.48
Tumor number (≥2/1) 0.206 2.37 0.62-9.03 0.162 0.43 0.13-1.41
Tumor size,cm (≥3/<3) 0.547 0.67 0.18-2.49 0.292 1.89 0.58-10.93
TNM stage 0.206 2.37 0.62-9.25 0.068 0.30 0.08-1.10
Differentiation 0.033 5.36 1.15-25.06 0.154 2.4 0.72-7.97
(well/moderate/poor)
TACE treatment/not 0.012 6.43 1.57-27.45 0.070 3.47 0.90-13.31
AFP,α-fetoprotein; TACE, Transarterial chemoembolization.
Zeng et al. BMC Cancer 2012, 12:584 Page 8 of 11
http://www.biomedcentral.com/1471-2407/12/584
consensus, identification of CSCs has been difficult
due to lack of specificity of markers and limitations of
model systems.
We reasoned that true HCC CSCs might be enriched
in tumor cells that survived doxorubicin-based che-
moembolization (TACE) and took advantage of the fact
that some, but not all patients at our center undergoing
liver transplantation for HCC underwent TACE prior to
transplant. We thus stained HCC specimens and adja-
cent liver tissue for CD133, CD44, CD90, and EpCAM.
Each of these has been previously reported to be asso-
ciated with HCC CSCs. CD133 was used to identify
CSCs in several types of tumors including HCC [19].
CD44, a stem cell biomarker, has been used as a target
to attempt to eradicate CSCs in HCC [17,24] and has
also been linked to invasion and metastatic potential
[25,26]. EpCAM, a progenitor cell marker, was previ-
ously correlated with poor prognosis of HCC [15,27],
and CD90 was reported as a key marker for the selection
of CSCs [16].
The results showed that all of these markers were
elevated in liver tumor tissues compared to adjacent
non-tumor liver, but there were considerable differences
between individual tumors. This suggests that the
expression patterns of various stem cell markers in
tumor initiating cells with stem/progenitor cell features
may be different in each HCC, possibly due to the het-
erogeneity of activated signaling pathways in normal
stem/progenitor cells where these tumor initiating cells
may originate. Expression of CD133 and EpCAM were
significantly elevated in post-TACE tumors. This finding
is similar to the recent observation that HCC tumors re-
curring post TACE frequently had a morphology sug-
gestive of a mixed hepatocholangiocellular phenotype
that stained positive for stem cell markers [11]. The
greater presence of CD133 and EpCAM positive cells in
the post-TACE samples could result either because this
cell population selectively survived treatment, or because
recurrent tumor growth resulted in a dedifferentiation
process that generated positive cells. The present study
is not able to distinguish between these possibilities. In
addition, since this was a retrospective study, we did not
have samples from these tumors before TACE, and the
decision to perform TACE was made on clinical
grounds. It is therefore possible that the TACE patients
had larger or more aggressive tumors. The TACE-
treated tumor did tend to be larger than the non-TACE
tumors but we were not able to detect any differences in
pre-op tumor growth rates or TMN score between the
two groups (Table 1).
Because of the possible difference between TACE-
treated and non-TACE treated tumors we analyzed re-
currence data separately for these two groups. We
observed that the intensity of EpCAM, but not CD133
staining was a strong predictor of tumor recurrence in
patients who were transplanted after TACE treatment.
This was not true for the other markers studied. It sup-
ports prior studies that have identified EpCAM as a
marker that best identified HCC-derived cells with
tumor forming potential [15,28].
The results obtained in this study show a significant
relationship between tumor recurrence rates and pre-
transplantation EpCAM expression in patients who under-
went pre-transplant TACE. Recurrence only occurred in
1 of 23 patients without TACE as compared to 4 of 16
patients who had had prior TACE and thus the infre-
quency of the event in the non-TACE group made it im-
possible to assess correlations.
Conclusion
Improvement of the ability to predict post-transplant
HCC recurrence would allow pre-transplant character-
ization to more efficiently allocate organs, possibly
increasing eligibility for patients with low recurrence risk
and reducing the overall recurrence rate. While the
understanding of histochemical markers in this study
and others is an important step, it cannot be immedi-
ately translated into clinical practice due to the fact that
HCC is not routinely biopsied, and heterogeneity within
tumors makes in doubtful that a needle biopsy would be
Table 7 Multivariate analyses of clinical and tumor
factors associated with Epcam in 39 HCC patients
Variable P value OR 95%CI
Differentiation (well/moderate/poor) 0.056 5.01 0.96-26.21
TACE Treatment/not 0.025 5.88 1.25-27.80
Months post transplant
















Figure 3 Proportion of post-TACE patients experiencing tumor
recurrence after transplantation. The 16 patients were stratified
by EpCAM staining intensity into high and low staining groups.
Proportion of patients experiencing radiologically documented
tumor recurrence is shown. For the high EpCAM staining patients,
4/10 recurred as compared to 0/6 low staining patients (P = 0.04).
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sufficient to make the required distinctions. Nonetheless,
a better understanding of the biology associated with
recurrence might allow better diagnostic studies, such as
serum markers, to have impact in the future.
If tumor growth and metastasis are indeed driven by
CSCs, this can explain why current chemotherapies,
developed largely against the bulk tumor mass, are able
to shrink the primary tumor, but are unable to provide a
lasting cure for the disease. It is likely that these residual
CSCs are able to survive, perhaps in circulation or other
extrahepatic sites, and result in tumor relapse after
transplantation. Better identification of CSC from tumor
tissue may therefore be useful to target future treat-
ments. Our study provides evidence EpCAM may prove
to be a useful marker for HCC recurrence after liver
transplantation and might be helpful in getting a better
prediction of recurrence in patients who have been
“downstaged” to fit into the Milan criteria. It will be im-
portant to replicate these results in larger cohort groups
and determine whether other stem cell markers can also
predict recurrence.
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